Literature DB >> 21301432

Balancing open source stem cell science with commercialization.

Aidan Courtney, Paul de Sousa, Carol George, Graeme Laurie, Joyce Tait.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21301432     DOI： 10.1038/nbt.1773

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Human tissue engineered products--drugs or devices?

Authors:  Alex Faulkner; Ingrid Geesink; Julie Kent; David FitzPatrick
Journal:  BMJ       Date:  2003-05-31

2.  The global stem cell patent landscape: implications for efficient technology transfer and commercial development.

Authors:  Karl Bergman; Gregory D Graff
Journal:  Nat Biotechnol       Date:  2007-04       Impact factor: 54.908
  2 in total
  4 in total

1.  Open science versus commercialization: a modern research conflict?

Authors:  Timothy Caulfield; Shawn He Harmon; Yann Joly
Journal:  Genome Med       Date:  2012-02-27       Impact factor: 11.117

2.  Hematopoietic stem cells meet induced pluripotent stem cells technology.

Authors:  Maria Teresa Esposito
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

3.  From banking to international governance: fostering innovation in stem cell research.

Authors:  Rosario Isasi; Bartha M Knoppers
Journal:  Stem Cells Int       Date:  2011-09-05       Impact factor: 5.443

Review 4.  LULL(ed) into complacency: a perspective on licenses and stem cell translational science.

Authors:  Mahendra S Rao
Journal:  Stem Cell Res Ther       Date:  2013-08-14       Impact factor: 6.832
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.